Get Premium to unlock powerful stock data

Bvf Inc Buys GH Research PLC, argenx SE, Syndax Pharmaceuticals Inc, Sells , Ionis Pharmaceuticals Inc, IDEAYA Biosciences Inc

Author's Avatar
insider
Aug 24, 2021
Article's Main Image
Investment company Bvf Inc (Current Portfolio) buys GH Research PLC, argenx SE, Syndax Pharmaceuticals Inc, Viracta Therapeutics Inc, Rain Therapeutics Inc, sells , Ionis Pharmaceuticals Inc, IDEAYA Biosciences Inc, CytomX Therapeutics Inc, Xenon Pharmaceuticals Inc during the 3-months ended 2021Q2, according to the most recent filings of the investment company, Bvf Inc. As of 2021Q2, Bvf Inc owns 70 stocks with a total value of $2.7 billion. These are the details of the buys and sells.

For the details of BVF INC's stock buys and sells, go to https://www.gurufocus.com/guru/bvf+inc/current-portfolio/portfolio

These are the top 5 holdings of BVF INC
  1. GH Research PLC (GHRS) - 9,275,156 shares, 7.55% of the total portfolio. New Position
  2. argenx SE (ARGX) - 651,204 shares, 7.35% of the total portfolio. Shares added by 110.34%
  3. Olema Pharmaceuticals inc (OLMA) - 6,661,503 shares, 6.99% of the total portfolio.
  4. Protagonist Therapeutics Inc (PTGX) - 3,754,095 shares, 6.31% of the total portfolio. Shares reduced by 5.19%
  5. Merus NV (MRUS) - 7,285,071 shares, 5.75% of the total portfolio.
New Purchase: GH Research PLC (GHRS)

Bvf Inc initiated holding in GH Research PLC. The purchase prices were between $19.25 and $21.73, with an estimated average price of $20.43. The stock is now traded at around $21.000000. The impact to a portfolio due to this purchase was 7.55%. The holding were 9,275,156 shares as of 2021-06-30.

New Purchase: Viracta Therapeutics Inc (VIRX)

Bvf Inc initiated holding in Viracta Therapeutics Inc. The purchase prices were between $7.55 and $12.95, with an estimated average price of $10.02. The stock is now traded at around $9.620000. The impact to a portfolio due to this purchase was 1.32%. The holding were 3,094,174 shares as of 2021-06-30.

New Purchase: Rain Therapeutics Inc (RAIN)

Bvf Inc initiated holding in Rain Therapeutics Inc. The purchase prices were between $15.08 and $20.3, with an estimated average price of $17.57. The stock is now traded at around $17.940000. The impact to a portfolio due to this purchase was 1.13%. The holding were 1,945,949 shares as of 2021-06-30.

New Purchase: Janux Therapeutics Inc (JANX)

Bvf Inc initiated holding in Janux Therapeutics Inc. The purchase prices were between $18.58 and $25.37, with an estimated average price of $22.27. The stock is now traded at around $29.520000. The impact to a portfolio due to this purchase was 1.1%. The holding were 1,176,681 shares as of 2021-06-30.

New Purchase: Ikena Oncology Inc (IKNA)

Bvf Inc initiated holding in Ikena Oncology Inc. The purchase prices were between $13.27 and $28.25, with an estimated average price of $18.64. The stock is now traded at around $11.850000. The impact to a portfolio due to this purchase was 0.93%. The holding were 1,767,399 shares as of 2021-06-30.

New Purchase: Day One Biopharmaceuticals Inc (DAWN)

Bvf Inc initiated holding in Day One Biopharmaceuticals Inc. The purchase prices were between $19 and $25.89, with an estimated average price of $20.97. The stock is now traded at around $27.000000. The impact to a portfolio due to this purchase was 0.78%. The holding were 918,975 shares as of 2021-06-30.

Added: argenx SE (ARGX)

Bvf Inc added to a holding in argenx SE by 110.34%. The purchase prices were between $257.11 and $319.92, with an estimated average price of $284.1. The stock is now traded at around $343.250000. The impact to a portfolio due to this purchase was 3.86%. The holding were 651,204 shares as of 2021-06-30.

Added: Syndax Pharmaceuticals Inc (SNDX)

Bvf Inc added to a holding in Syndax Pharmaceuticals Inc by 1420.53%. The purchase prices were between $13.42 and $25.18, with an estimated average price of $18.46. The stock is now traded at around $16.810000. The impact to a portfolio due to this purchase was 1.49%. The holding were 2,486,429 shares as of 2021-06-30.

Added: Arcus Biosciences Inc (RCUS)

Bvf Inc added to a holding in Arcus Biosciences Inc by 49.13%. The purchase prices were between $22.75 and $35.77, with an estimated average price of $28.5. The stock is now traded at around $28.950000. The impact to a portfolio due to this purchase was 0.95%. The holding were 2,797,822 shares as of 2021-06-30.

Added: 4D Molecular Therapeutics Inc (FDMT)

Bvf Inc added to a holding in 4D Molecular Therapeutics Inc by 94.54%. The purchase prices were between $22.2 and $43.38, with an estimated average price of $30.89. The stock is now traded at around $30.120000. The impact to a portfolio due to this purchase was 0.88%. The holding were 2,005,862 shares as of 2021-06-30.

Added: Therapeutics Acquisition Corp (RACA)

Bvf Inc added to a holding in Therapeutics Acquisition Corp by 258.99%. The purchase prices were between $9.91 and $10.54, with an estimated average price of $10.18. The stock is now traded at around $10.274300. The impact to a portfolio due to this purchase was 0.77%. The holding were 2,772,226 shares as of 2021-06-30.

Added: Replimune Group Inc (REPL)

Bvf Inc added to a holding in Replimune Group Inc by 99.15%. The purchase prices were between $28.5 and $39.37, with an estimated average price of $34.17. The stock is now traded at around $31.170000. The impact to a portfolio due to this purchase was 0.66%. The holding were 918,928 shares as of 2021-06-30.

Sold Out: (FPRX)

Bvf Inc sold out a holding in . The sale prices were between $37.65 and $38, with an estimated average price of $37.89.

Sold Out: Ionis Pharmaceuticals Inc (IONS)

Bvf Inc sold out a holding in Ionis Pharmaceuticals Inc. The sale prices were between $34.54 and $47.25, with an estimated average price of $39.32.

Sold Out: IDEAYA Biosciences Inc (IDYA)

Bvf Inc sold out a holding in IDEAYA Biosciences Inc. The sale prices were between $17.76 and $24.83, with an estimated average price of $20.63.

Sold Out: CytomX Therapeutics Inc (CTMX)

Bvf Inc sold out a holding in CytomX Therapeutics Inc. The sale prices were between $6.33 and $9.91, with an estimated average price of $7.78.



Here is the complete portfolio of BVF INC. Also check out:

1. BVF INC's Undervalued Stocks
2. BVF INC's Top Growth Companies, and
3. BVF INC's High Yield stocks
4. Stocks that BVF INC keeps buying
Rating:
NaN / 5 ( votes)
Author's Avatar
WRITTEN BY

GuruFocus Screeners

Related Articles

Q&A with Gurus